Source-grounded facts extracted from ELITE PHARMACEUTICALS INC /NV/'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
ELITE PHARMACEUTICALS INC /NV/ reported third quarter of fiscal year 2024 ended December 31, 2023 results: revenue $15.5 million.
“Consolidated revenues for the three-month period ended December 31, 2023, were $15.5 million, an increase of $6.3 million or 68% as compared to the comparable period of the prior fiscal year.”
ELITE PHARMACEUTICALS INC /NV/ reported the second quarter of fiscal year 2024 ended September 30, 2023 results: revenue $14.2 million, net income $14.9 million.
“Consolidated revenues for the three-month period ended September 30, 2023, were $14.2 million, an increase of $5.6 million or 64.9% as compared to the comparable period of the prior fiscal year.”
Carter J. Ward was appointed as chief financial officer, secretary, and treasurer at ELITE PHARMACEUTICALS INC /NV/.
“On September 5, 2023 (the “Effective Date”), Carter J. Ward was appointed as the Company’s chief financial officer, secretary, and treasurer.”
ELITE PHARMACEUTICALS INC /NV/ reported first quarter of fiscal year 2024 ended June 30, 2023 results: revenue $9.0 million, net income $1.1 million.
“Consolidated revenues for the three-month period ended June 30, 2023, were $9.0 million, an increase of $1.3 million or 16.9% as compared to the comparable period of the prior fiscal year. Operating profits were $1.6 million, an increase of $0.6 million or 60% from the comparable period of the prior year. Net income attributable to common shareholders was $1.1 million, an increase of $0.8 million or 267% from the comparable period of the prior year.”
ELITE PHARMACEUTICALS INC /NV/ dismissed Buchbinder Tunick & Company LLP as its auditor.
“The Audit Committee also dismissed Buchbinder Tunick & Company LLP (“Buchbinder”) as the Company’s independent registered public accounting firm, effective as of July 12, 2023.”
ELITE PHARMACEUTICALS INC /NV/ engaged Mazers USA LLP as its auditor.
“Company”) approved the appointment, effective July 11, 2023, of Mazers USA LLP (“Mazers”) as the Company’s new independent registered public accounting firm to audit the Company’s consolidated financial statements for the year ending”
ELITE PHARMACEUTICALS INC /NV/ reported the fiscal year ended March 31, 2023 results: revenue $34.2 million, net income $3.6 million.
“Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCBB: ELTP), a specialty pharmaceutical company developing niche generic products, announced results for the fiscal year ended March 31, 2023 (“Fiscal 2023”). Consolidated revenues for Fiscal 2023 were $34.2 million, an increase of $1.9 million or 5.9% as compared to the comparable period of the prior fiscal year. Operating profits were $3.7 million, a decrease of $1.4 million from the comparable period of the prior year, and net income was $3.6 million.”
Robert Chen departed as Chief Financial Officer at ELITE PHARMACEUTICALS INC /NV/.
“On April 27, 2023, Elite Pharmaceuticals, Inc., a Nevada corporation (the “Registrant”), entered into an employment agreement with Mark Pellegrino to serve as the Registrants’ Chief Financial Officer effective May 1, 2023, replacing Robert Chen.”
Mark Pellegrino was appointed as Chief Financial Officer at ELITE PHARMACEUTICALS INC /NV/.
“On April 27, 2023, Elite Pharmaceuticals, Inc., a Nevada corporation (the “Registrant”), entered into an employment agreement with Mark Pellegrino to serve as the Registrants’ Chief Financial Officer effective May 1, 2023, replacing Robert Chen.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.